Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: An analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-Term extension studies

Mark H. Rozenbaum, Andrea Garcia, Daniel Grima, Diana Tran, Rahul Bhambri, Michelle Stewart, Benjamin Li, Bart Heeg, Maarten Postma, Ahmad Masri

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Aim: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) showed that tafamidis reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to estimate the impact of tafamidis on survival and quality-Adjusted life-years (QALYs). Methods and results: A multi-state, cohort, Markov model was developed to simulate the disease course of ATTR-CM throughout a lifetime. For survival extrapolation, survival curves were fitted by treatment arm and New York Heart Association (NYHA) Class I/II (68% of patients) and NYHA Class III (32% of patients) cohorts using the individual patient-level data from both the ATTR-ACT and the corresponding long-Term extension study. Univariate and multivariate sensitivity analyses were conducted. The predicted mean survival for the total population (NYHA Class I/II + III) was 6.73 years for tafamidis and 2.85 years for the standard of care (SoC), resulting in an incremental mean survival of 3.88 years [95% confidence interval (CI) 1.32-5.66]. Of the 6.73 life-years, patients on tafamidis spend, on average, 4.82 years in NYHA Class I/II, while patients on SoC spend an average of 1.60 life-years in these classes. The combination of longer survival in lower NYHA classes produced a QALY gain of 5.39 for tafamidis and 2.11 for SoC, resulting in 3.29 incremental QALYs (95% CI 1.21-4.74) in favour of tafamidis. Conclusion: Based on the disease simulation model results, tafamidis is expected to more than double the life expectancy and QALYs of ATTR-CM patients compared to SoC. Longer-Term follow-up data from the ATTR-ACT extension study will further inform these findings. Clinical trials.gov identifier: NCT01994889 (date of registration: 26 November 2013).

Original languageEnglish (US)
Pages (from-to)529-538
Number of pages10
JournalEuropean Heart Journal - Quality of Care and Clinical Outcomes
Volume8
Issue number5
DOIs
StatePublished - Sep 1 2022

Keywords

  • Amyloidosis
  • Cardiomyopathy
  • Mortality
  • Tafamidis
  • Transthyretin

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: An analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-Term extension studies'. Together they form a unique fingerprint.

Cite this